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10 mg tablet-dose of zolpidem tatrate. A total of 12 plasma samples were collected over a 12 h period after
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parameters of zolpidem tatrate among the ﬁve ethnic groups (P40.05). However, there were statistically
signiﬁcant differences between males and females for the pharmacokinetic parameters (Po0.05). The
metabolism of zolpidem tatrate in males was faster than in females. Results indicate that ethnicity has no
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subjects. However, an effect of gender on the pharmacokinetics of zolpidem tatrate can be noted.
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Comparative pharmacokinetics of zolpidem tartrate 1471. Introduction
Zolpidem (N,N,6-trimethyl-2-(4-methylphenyl)imidazo[1,2-a]pyridine-
3-acetamide hemitartrate) is a non-benzodiazepine imidazopyridine
hypnotic which has been use for the treatment of insomnia and the
induction of anesthesia1–3. It was reported that zolpidem can be rapidly
and completely absorbed from the gastrointestinal tract with a limited
ﬁrst-pass effect with an absolute bioavailability of approximately 70%.
In vitro studies using human liver microsomes and heterologously
expressed human cytochromes P450 indicated that zolpidem undergoes
extensive hepatic metabolism with up to 96% eliminated in the bile,
urine and feces as inactive hydroxylated metabolites by a series of CYP
enzymes including CYP3A4, CYP2C9, CYP1A2, CYP2D6 and
CYP2C194,5. Differences in the expression or activity of cytochromes
P450 (CYP), an important family of drug-metabolising enzymes, can
lead to inter-individual differences in the response to drugs and thus
result in adverse effects as a result of genetic variations6. Ethnic
differences in CYP3A4 substrate pharmacokinetics have been
observed. After being given oral triazolam, Asians achieved higher
maximum plasma concentrations (Cmax) and had a shorter time to
reach Cmax as compared to Caucasians
7.
China is a multi-ethnic country which has a Han group and 55
ethnic minorities that includes the main groups of Mongolian,
Korean, Hui, Uygur and Tibetan. Each ethnic group has developed
its own population genetics and characteristics as a result of
geographical and cultural separation, as well as differences in
origin. Importantly, genetic differences in various ethnic Chinese
populations may contribute to differences in drug responses8–11.
For example, the pharmacokinetic parameters of tinidazole clear-
ance were different among Han, Mongolian, Korean, Hui and
Uigur healthy subjects after a single oral dose. The t1/2, AUC(0–1),
CL and ke values were signiﬁcantly different between Uigur and
other Chinese ethnic groups, and the clearance of tinidazole in
Uigur subjects was increased by 20% compared to that of other
ethnicities12. This ethnic difference was also observed in a
comparative pharmacokinetic study on midazolam clearance in
healthy volunteers of the Han, Mongolian, Uygur, Hui and
Korean13. For this reason using the same dosage regimen of
zolpidem for every ethnic group may be inappropriate. Therefore,
we characterized the pharmacokinetics of oral zolpidem among
different Chinese ethnic groups, including Han, Mongolian,
Uygur, Hui and Korean. This is the ﬁrst evaluation of the effect
of ethnicity on zolpidem pharmacokinetics in healthy Chinese
volunteers.2. Materials and methods
This was a controlled study which was conducted in Shenyang
Northern Hospital (Shenyang, China) in accordance with the
principles of the Declaration of Helsinki and Good Clinical
Practice, and the protocol was approved by the Ethical Committee
of Shenyang Northern Hospital (Shenyang, China). Written
informed consent was obtained from all participants before
enrollment in the study. The volunteers were free to withdraw
from the study at any time without any reason.
2.1. Inclusion and exclusion criteria
The ethnic origin of each subject's parents, maternal and paternal
grandparents was required to ensure homogeneity. Principal exclusion
criteria included medical or psychiatric conditions that could haveaffected the performance of the pharmacokinetics study, positive
screening test for alcohol, smoking or drugs of abuse within 14 days
before the study and use of any prescription or over-the-counter
medication within 7 days before the study. All females were tested
during the luteal phase of their menstrual cycle. There was no
signiﬁcant difference in average height or weight between the ﬁve
ethnic groups.
2.2. Study design
The current study was designed as a single-dose, parallel-group
protocol performed in young healthy male and female adults
across ﬁve different ethnicities in China. Following an overnight
fast, an oral dose of 10 mg zolpidem tablets (Hangzhou Sanoﬁ-
Aventis Minsheng Pharmaceutical Co., Ltd., Hangzhou, China)
was given to each subject. All subjects were not allowed to
consume food or beverage until the 2 h blood sample had been
obtained. The lunch and dinner provided during experiment was
low fat and given at 4 and 9 h after administration, respectively.
Participants were required to abstain from alcohol, grapefruit,
caffeine-containing products and strenuous exercise during the
course of the study. During the test period, all participants
remained under close medical supervision.
2.3. Blood sampling and analysis
Blood samples (4 mL) were collected into heparinized tubes prior
to zolpidem administration (0 h) and at 0.25, 0.5, 0.75, 1, 1.5, 2, 3,
4, 6, 9 and 12 h following oral dosage. Plasma samples were
immediately separated by centrifugation and the plasma was stored
at –25 1C in polypropylene tubes until analysis.
Concentrations of zolpidem in plasma were analyzed by means of
validated high-performance liquid chromatography14. Brieﬂy, 0.5 mL
plasma sample was pipetted into a 15 mL centrifuge tube to which
was added 100 μL methanol, 50 μL internal standard solution
(50 μg/L alfuzosin hydrochloride) and 50 μL sodium hydrate
solution (4.0 mol/L). The mixture was vortex-mixed for 1 min, then
after addition of 5 mL ether, vortex-mixed for 3 min and centrifuged
at 3000 rpm for 10 min. The organic layer was transferred to a clean
tube and evaporated under a steady stream of nitrogen to dryness in
a water bath at 37 1C. The residue was reconstituted in 100 μL
mobile phase and vortex-mixed for 30 s, and a 20 μL aliquot of
supernatant was injected into the HPLC system.2.4. Pharmacokinetic and statistical analysis
Pharmacokinetic parameters for zolpidem were estimated by non-
compartmental methods using the Drug and Statistics software
(DAS, version 2.0, Mathematical Pharmacology Professional
Committee of China). For each subject, the Cmax and the time
reach to Cmax (Tmax) were determined by visual inspection of
plasma concentration-time proﬁles. The terminal elimination rate
constant (λz) was determined by linear regression of the terminal
portion of the log concentration-time proﬁle. The terminal half-life
(t1/2Z) was calculated as 0.693/λz. The area under the curve to the
last measured point (AUC0–t) was calculated using the trapezoidal
rule. The area under the plasma concentration versus time curve from
0 h to inﬁnite time (AUC0–1) was calculated as the sum of AUC0–t
and Clast/λz, while Clast was the last quantiﬁable concentration. Total
body weight-normalized plasma oral clearance (CLz/F) was
T. Guo et al.148calculated from the ratio of D/(AUC0–1 W), where D represents
dosage and W represents total body weight of participant. The total
body weight-normalized apparent volume of distribution (Vz/F) was
calculated as CLz/(λz W).
Statistical analyses were performed by using SPSS software
(version 16.0; SPSS Inc., Chicago, IL, USA). Normal distribution
and equality of variances of pharmacokinetic parameter values for
each ethnic group were determined by Kolmogoroff-Smirnov test
or Levene's test, prior to the statistic analyses of the selected
parameter. Differences among the various groups were determined
using either Analysis of variance (ANOVA) or Kruskal–Wallis
rank test. Po0.05 was considered statistically signiﬁcant.3. Results
3.1. Demographic data
Fifty healthy young male and female volunteers were recruited
from 2007 to 2009 from Shenyang in Liaoning, Chifeng in Inner
Mongolia, Yanji in Jilin, Urumqi in Xinjiang, and Yinchuan in
Ningxia, thus comprising the ﬁve ethnic groups (n¼10/group).
After collection of the plasma samples, the same researcher
determined the plasma concentration of zolpidem as described in
Materials and Methods. One Hui female subject withdrew from the
study after the oral administration at her own request. There was
no signiﬁcant difference in height and weight among ﬁve ethnic
groups (Table 1).
3.2. Method validation
The regression equation for zolpidem concentration was described
as: y¼–0.022þ0.041x (r¼0.9994), where y means the plasma
concentration of zolpidem, and x mean the ratio of peak area of
zolpidem to that of internal standard. The calibration curve was
in good linearity within the range of 2.0–250.0 ng/mL with inter-
and inter-day relative standard deviations of less than 8.8%. TheTable 1 Participant demographic data for subjects of ﬁve ethnic gro
Character Han Mongolian
Gender 5M, 5F 5M, 5F
Height (cm) 16475 16876
Weight (kg) 55.075.2 57.875.1
Age (years) 2270.9 20.871.3
M: male; F: female.
Figure 1 HPLC chromatograms of zolpidem tatrate in plasma. A: a blank
tatrate and; C: a volunteer plasma sample. 1: alfuzosin hydrochloride (interetention times of zolpidem and internal standard were 9.3 and
5.3 min, respectively (Fig. 1).3.3. Pharmacokinetics
The mean plasma concentration vs. time curves for zolpidem
clearance for different ethnic subjects and genders are depicted in
Figs. 2 and 3. Pharmacokinetic parameters of the different ethnicities
and genders are presented in Tables 2 and 3. Comparative analysis of
the pharmacokinetic parameters indicated that there were no sig-
niﬁcant differences in all pharmacokinetic parameters among groups
of Han, Mongolian, Uygur, Hui and Korean (P40.05). The average
t1/2 values of 2.0470.47 h (Korean), 2.170.75 h (Uigur) were 1.4
times shorter than that of the Hui (2.8470.81 h), and the CL value of
31.87735.96 L/h (Uigur) was higher than that of the other four
groups; however, there were large individual variations within each
group, and differences were not statistically signiﬁcant.
There were signiﬁcant differences between males and females
(Po0.05). The Cmax value and Vd value of females were
signiﬁcant different from those of males, but no signiﬁcant
differences were found after weight-normalization. The t1/2 value
of 2.6370.70 h (female) was signiﬁcantly longer than that of
males (Po0.002). The CL value 27.51724.69 L/h was signiﬁ-
cantly higher in males than in females (Po0.01), and AUC value
507.867246.34 μg.h/L (male) was signiﬁcantly lower than in
females (Po0.001). The differences in CL and AUC retained
signiﬁcance after weight normalization.3.4. Safety assessments
One Mongolian participant suffered from vomiting and 2–3
suffered from nausea in each ethnic group. There were no serious
adverse experiences in the other subjects throughout the study.ups.
Uigur Korean Hui
5M, 5F 5M, 5F 5M, 4F
17176 16578 16676
58.576.9 55.077.6 57.876.0
20.371.5 22.470.5 21.371.9
plasma sample; B: a blank plasma sample spiked with IS and zolpidem
rnal standard); 2: zolpidem tatrate.
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The objective of this investigation was to characterize the ethnic
and gender-related pharmacokinetics of zolpidem in Chinese Han,Figure 2 Mean plasma concentration-time proﬁles of zolpidem
tartrate tablet in healthy volunteers of ﬁve ethnic groups (Han,
Mongolian, Uygur and Korean: n¼10; Hui, n¼9).
Figure 3 Mean plasma concentration-time proﬁles of zolpidem tartrate
tablet in male and female healthy volunteers (nmale¼25, nfemale¼24).
Table 2 Pharmacokinetic parameters for 49 healthy subjects after a
Parameter Han Mongolian Kor
Cmax (μg/L) 190.81770.59 221.857109.97 178
Tmax (h) 0.9370.47 0.970.37 0
t1/2 (h) 2.2270.77 2.4870.6 2
Vd (L) 49.5277.99 58.4736.43 53
CL (L/h) 17.95710.06 18.76715.1 19
AUC0–12 h (μg  h/L) 624.467192.15 7707405.64 578
AUC0–1 (μg  h/L) 649.587210.17 808.857434.10 597
Table 3 The comparison of pharmacokinetic parameters between m
tartrate tablet (Means7SD).
Parameter Malea
Cmax (μg/L) 169.11770.20
Tmax (h) 0.9470.34
t1/2 (h) 2.0270.60
Vd (L) 66.59731.64
CL (L/h) 27.51724.69
AUC0–12 h (μg  h/L) 507.867246.34
AUC0–1 (μg  h/L) 524.787260.03
an¼25.
bn¼24.
P1 with weight-normalization; P2, without weight-normalization.Mongolian, Uygur, Hui and Koreans. Ten healthy volunteers of
each ethnicity were selected according to the “Guidance for
Clinical Pharmacokinetic Study of Chemicals in China” which
determined that the sample size in each group in a Phase I
pharmacokinetic study might be 8–12 healthy volunteers with the
sex ratio at 1:1. In order to ensure the homogeneity of ethnicity, all
volunteers were students recruited from the local universities
whose parents and grandparents had the same descent.
The results indicate that there were no signiﬁcant differences in
any pharmacokinetic parameter among ﬁve groups, indicating that
ethnicity has no impact on the pharmacokinetics of zolpidem for
Han, Mongolian, Uygur, Hui and Koreans. However, individual
gender factors should be considered; for example, the half-life of
zolpidem in females was statistically signiﬁcant longer than in
males. The CL value in males was about 2 times higher than that
of females, and the AUC value of females was about 1.5 times
larger than males. These differences in CL and AUC values were
signiﬁcant, with and without normalization for body weight. These
observations are consistent with previous reports1,15. The sex
difference in the pharmacokinetics of zolpidem is similar to that
seen for estrogen16.5. Conclusions
The results of the current study indicate that no dose adjustment is
required when zolpidem is given to Han, Mongolian, Uygur, Hui
or Korean subjects. However, gender has a signiﬁcant impact on
the oral clearance and half-life of zolpidem. Whether the sex
difference might lead to adverse effects should be considered when
the same dosage is given to male or female patients.single oral dose of 10 mg zolpidem tartrate tablet (Means7SD).
ean Hui Uigur P
.13743.07 199.64755.48 175.12778.19 0.671
.9870.22 0.7570.18 0.7870.25 0.368
.0470.47 2.8470.81 2.170.75 0.088
.07712.89 58.98734.76 68.74727.34 0.239
.5678.32 15.82712.32 31.87735.96 0.160
.897216.25 742.117234.34 493.037240.37 0.166
.487227.97 803.947272.08 510.997254.54 0.160
ale and female subjects after a single oral dose of 10 mg zolpidem
Femaleb P1 P2
217.83771.27 0.020 0.354
0.7970.28 0.104
2.6370.70 0.002
47.50710.30 0.008 0.098
13.5875.78 0.011 0.029
784.207240.36 0.001 0.010
831.637266.67 0.000 0.008
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